Listed

Relmada Therapeutics, Inc.

RLMDNasdaqCIK 1553643HealthcareFiscal year ends Dec 31

Reports and events: 239 filings

Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.

What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.

Relmada Therapeutics, Inc., Reports and events
FiledFormWhat it isAccession number
2023-11-0816:05 ET10-QQuarterly reportPeriod 2023-09-300001213900-23-084737
2023-11-0816:01 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001213900-23-084735
2023-10-1109:00 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001013762-23-002985
2023-10-1017:18 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001013762-23-002900
2023-10-0408:53 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001013762-23-001391
2023-09-2016:47 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001213900-23-078049
2023-09-0609:23 ET8-K5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits0001213900-23-074165
2023-08-1016:54 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001213900-23-065674
2023-08-0816:29 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001213900-23-064577
2023-08-0816:01 ET10-QQuarterly reportPeriod 2023-06-300001213900-23-064519
2023-05-2516:28 ET8-K5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits0001213900-23-043101
2023-05-1517:29 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001213900-23-040004
2023-05-1116:48 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001213900-23-038577
2023-05-1116:07 ET10-QQuarterly reportPeriod 2023-03-310001213900-23-038533
2023-04-1909:25 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001213900-23-030851
2023-03-3109:00 ETDEF 14AProxy statementPeriod 2023-05-250001213900-23-025007
2023-03-2316:49 ET10-KAnnual reportPeriod 2022-12-310001213900-23-022463
2023-03-2316:05 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001213900-23-022428
2023-03-1308:30 ET8-K7.01 Regulation FD disclosure0001213900-23-019392
2023-01-1717:34 ET8-K1.01 Entry into a material agreement; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits0001213900-23-002865
2023-01-0908:38 ET8-K7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits0001213900-23-001518
2023-01-0517:28 ET8-K1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits0001213900-23-001162
2022-12-2817:05 ET8-K1.01 Entry into a material agreement; 9.01 Financial statements and exhibits0001213900-22-083290
2022-12-0716:58 ET8-K7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits0001213900-22-078255
2022-11-1406:10 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001213900-22-071463
2022-11-1017:04 ET8-K2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001213900-22-071296
2022-11-1016:06 ET10-QQuarterly reportPeriod 2022-09-300001213900-22-071154
2022-10-1309:21 ET8-K7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits0001213900-22-063664
2022-09-2217:19 ET8-K1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits0001213900-22-058066
2022-09-2016:32 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001213900-22-057439
2022-08-1116:48 ET10-QQuarterly reportPeriod 2022-06-300001213900-22-046934
2022-06-0109:22 ET8-K5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits0001213900-22-030586
2022-05-0516:54 ET8-K2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits0001213900-22-024268
2022-05-0516:05 ET10-QQuarterly reportPeriod 2022-03-310001213900-22-024229
2022-04-1116:15 ETDEF 14AProxy statementPeriod 2022-05-250001213900-22-019196
2022-03-2507:53 ET10-KAnnual reportPeriod 2021-12-310001213900-22-015012
2022-03-2316:23 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001213900-22-014492
2022-03-0716:05 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001213900-22-010929
2022-02-2306:04 ET8-K7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits0001213900-22-008783
2021-12-2217:21 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001213900-21-067091
2021-12-2017:21 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001213900-21-066436
2021-12-1317:06 ET8-K1.01 Entry into a material agreement; 9.01 Financial statements and exhibits0001213900-21-065014
2021-12-0717:15 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001213900-21-063985
2021-11-2310:21 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001213900-21-061444
2021-11-1508:26 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001213900-21-058993
2021-11-1209:10 ET10-QQuarterly reportPeriod 2021-09-300001213900-21-058454
2021-10-0717:00 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001213900-21-051860
2021-08-1016:03 ET10-QQuarterly reportPeriod 2021-06-300001213900-21-041369
2021-07-2016:45 ET8-K1.01 Entry into a material agreement0001213900-21-037756
2021-05-2017:20 ET8-K5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits0001213900-21-028217

Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Nov 13, 2026, 15:42 ET. Listed shows no prices and gives no investment advice.